Diabetic Nephropathy
|
0.200 |
Biomarker
|
disease |
RGD |
The expressions of NDUFS3 and TGF-β1 in DN rats were increased.
|
22903132 |
2012 |
Diabetic Nephropathy
|
0.200 |
Therapeutic
|
disease |
RGD |
Telmisartan improves kidney function through inhibition of the oxidative phosphorylation pathway in diabetic rats.
|
22591908 |
2012 |
Disorder of the optic nerve
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Down Syndrome
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
The protein levels of complex I 30-kDa subunit were significantly decreased in cerebral cortex of fetal DS brain.
|
11771736 |
2001 |
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dystonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Encephalopathies
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Encephalopathy, Subacute Necrotizing, Infantile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome.
|
14729820 |
2004 |
Encephalopathy, Subacute Necrotizing, Juvenile
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome.
|
14729820 |
2004 |
Failure to Thrive
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Fasting blood glucose measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.
|
22885924 |
2012 |
Fasting blood sugar result
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.
|
22885924 |
2012 |
Feeding difficulties
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Fetal Distress
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Fetal Growth Retardation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Focal T2 hyperintense basal ganglia lesion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Focal T2 hyperintense brainstem lesion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Generalized hypotonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Graft-vs-Host Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The incidences of grades II-IV acute graft-versus-host disease (GVHD) and chronic GVHD were 34 (95% CI 30-37%) and 51 (95% CI 46-56%), respectively.
|
29713245 |
2018 |
hearing impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model.
|
25231249 |
2015 |